Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Fox Chase, Temple Researchers Investigate Perceptions of Clinical Trial Participation Among African American Patients
PHILADELPHIA (September 14, 2020)—Researchers at Fox Chase Cancer Center and Temple University College of Public Health recently published survey results that explore the perceptions and concerns among African American patients regarding participation in cancer clinical trials.
“We were really interested in examining the barriers for underrepresented communities’ participation in clinical trials,” said Linda Fleisher, PhD, MPH, the co-principal investigator for the study and associate research professor in the Cancer Prevention and Control Program at Fox Chase.
Sarah Bauerle Bass, PhD, MPH, an associate professor at Fox Chase and director of the Risk Communication Laboratory at Temple, was co-principal investigator for the study. The lead author was Mohammed Alhajji, PhD, MPH, who was a doctoral candidate and research assistant in the lab when the research was conducted.
“We were interested in understanding the reasons why some African Americans decide to participate,” Fleisher said, “in hopes of developing interventions that address the underrepresentation of African Americans in cancer trials so that our clinical trial results are inclusive of diverse populations.”
The researchers recruited an equal number of African American patients who had participated in clinical cancer trials along with those who had not. Patients were recruited from both Fox Chase and Temple. Researchers then conducted a survey with those groups to clarify whether these individuals were offered clinical trials, what beliefs they held about clinical trials, and what types of barriers they believed existed to participating in these trials.
Results of the survey showed that perceptions among the groups differed significantly in three areas: helpfulness of clinical trials, facilitators to participate in clinical trials, and barriers to participating in clinical trials.
“We found that those who did participate had stronger positive beliefs about clinical trials. We also found that those who had not participated were more afraid to be part of clinical trials and were worried about their health insurance. They were also concerned they might become sicker,” said Fleisher. “Another interesting point was that some of the individuals who hadn’t participated said no one ever talked to them about a clinical trial.”
Analysis of the results indicated that those who were not asked about clinical trials and had not participated differed significantly in their views in all areas compared with those who had participated. Additionally, clinical trial participants reported significantly lower levels of decisional conflict in most items compared to those who had not been asked to participate and those who had been asked but declined to participate.
Fleisher added that the study illuminates the need to design more tailored interventions around clinical trials. “Understanding these barriers can help researchers design more culturally appropriate interventions and develop tools for providers,” she said.
“Concerns about getting sicker or health insurance need to be addressed. It also speaks to the need for this dialogue between patients and their providers around these kinds of emotional concerns,” said Fleisher. “By addressing these concerns we may find that, particularly among African American patients or patients who have more concerns, we’re able to help them make more informed decisions about participating.”
The study, “Comparing Perceptions and Decisional Conflict Towards Participation in Cancer Clinical Trials Among African American Patients Who Have and Have Not Participated,” was published in the Journal of Cancer Education.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427